- Home
- AXIL vs IMMX Comparison
AXIL vs IMMX Comparison
Compare AXIL & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- IMMX
- Stock Information
- Founded
- AXIL 2015
- IMMX 2014
- Country
- AXIL United States
- IMMX United States
- Employees
- AXIL N/A
- IMMX N/A
- Industry
- AXIL Package Goods/Cosmetics
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- AXIL Consumer Discretionary
- IMMX Health Care
- Exchange
- AXIL Nasdaq
- IMMX Nasdaq
- Market Cap
- AXIL 43.9M
- IMMX 50.1M
- IPO Year
- AXIL N/A
- IMMX 2021
- Fundamental
- Price
- AXIL $5.02
- IMMX $1.61
- Analyst Decision
- AXIL
- IMMX Strong Buy
- Analyst Count
- AXIL 0
- IMMX 1
- Target Price
- AXIL N/A
- IMMX $7.00
- AVG Volume (30 Days)
- AXIL 12.2K
- IMMX 48.0K
- Earning Date
- AXIL 04-09-2025
- IMMX 05-08-2025
- Dividend Yield
- AXIL N/A
- IMMX N/A
- EPS Growth
- AXIL 135.54
- IMMX N/A
- EPS
- AXIL 0.25
- IMMX N/A
- Revenue
- AXIL $26,554,439.00
- IMMX N/A
- Revenue This Year
- AXIL N/A
- IMMX N/A
- Revenue Next Year
- AXIL N/A
- IMMX N/A
- P/E Ratio
- AXIL $19.77
- IMMX N/A
- Revenue Growth
- AXIL N/A
- IMMX N/A
- 52 Week Low
- AXIL $3.54
- IMMX $1.26
- 52 Week High
- AXIL $13.24
- IMMX $3.13
- Technical
- Relative Strength Index (RSI)
- AXIL 26.94
- IMMX 44.76
- Support Level
- AXIL $6.83
- IMMX $1.36
- Resistance Level
- AXIL $7.53
- IMMX $1.90
- Average True Range (ATR)
- AXIL 0.67
- IMMX 0.15
- MACD
- AXIL -0.24
- IMMX -0.00
- Stochastic Oscillator
- AXIL 8.81
- IMMX 47.21
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.